Fisher & Paykel Healthcare dodges worst of US tariff risk: Jarden

Fisher & Paykel Healthcare dodges worst of US tariff risk: Jarden
About 43% of Fisher & Paykel Healthcare’s revenue comes from the US. (Image: Supplied)
John Anthony
Jarden has raised its rating and target share price for Fisher & Paykel Healthcare by 10%, as Thursday’s US tariff announcements proved less damaging than expected.Following US President Donald Trump’s unveiling of “Liberation Day” tariffs, shares in Fisher & Paykel Healthcare (FPH), a company with significant export exposure to the US, traded as low as $32.60 in the wake of the announcement on Thursday. They were currently at $34.80.In a research note released late Thursday evening, Jarden analysts Adrian Allbon...

More Economy

‘Teflon Man’ Neil Quigley’s next big job
Finance Analysis

Pattrick Smellie: ‘Teflon Man’ Neil Quigley’s next big job

Is the RBNZ lining up a Canadian replacement for Adrian Orr?

August rate cut still on the cards
Economy

August rate cut still on the cards

Annual inflation increased 2.7% in the 12 months to the June quarter. 

Rebecca Howard 21 Jul 2025
Annual inflation up 2.7% in June year
Economy

Annual inflation up 2.7% in June year

Annual inflation slightly lower than economists expected. 

Rebecca Howard 21 Jul 2025
June inflation forecasts approach 3%
Economy

June inflation forecasts approach 3%

Inflation may test the upper limit of the RBNZ's target range. 

Andy Macdonald 21 Jul 2025